Heterogeneity of Bcl-2 expression in metastatic breast carcinoma

Modern Pathology

Volumn 23, Issue 8, 2010, Pages 1089-1096

  Subhawong, Andrea Proctor ^a   Nassar, Hind ^a   Halushka, Marc K ^a   Illei, Peter B ^a   Vang, Russell ^a   Argani, Pedram ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

bcl 2; breast carcinoma; metastasis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN BCL 2;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; HUMAN; HUMAN TISSUE; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; UPREGULATION;

ADULT; AGED; AUTOPSY; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; ESTROGEN RECEPTOR ALPHA; FATAL OUTCOME; FEMALE; HUMANS; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 77955172888     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2010.93     Document Type: Article

References (30)

1. Basu A, Rowan BG. Genes related to estrogen action in reproduction and breast cancer. Front Biosci 2005;10:2346-2372.
2. Agarwal ML, Taylor WR, Chernov MV, et al. The p53 network. J Biol Chem 1998;273:1-4.
3. Frenzel A, Grespi F, Chmelewskij W, et al. Bcl2 family proteins in carcinogenesis and the treatment of cancer. Apoptosis 2009;14:584-596.
4. Zinkel S, Gross A, Yang E. BCL2 family in DNA damage and cell cycle control. Cell Death Differ 2006;13:1351-1359.
5. Borner C. Diminished cell proliferation associated with the death-protective activity of Bcl-2. J Biol Chem 1996;271:12695-12698.
6. Reed JC, Miyashita T, Takayama S, et al. BCL-2 family proteins: regulators of cell death involved in the pathogenesis of cancer and resistance to therapy. J Cell Biochem 1996;60:23-32. (Pubitemid 26047917)
7. Park S, Kim H, Song B. Down regulation of bcl2 expression in invasive ductal carcinomas is both estrogen-and progesterone-receptor dependent and associated with poor prognostic factors. Pathol Oncol Res 2002;8:26-30.
8. Strasser A, Huang DC, Vaux DL. The role of the bcl-2/ced-9 gene family in cancer and general implications of defects in cell death control for tumourigenesis and resistance to chemotherapy. Biochim Biophys Acta 1997;1333:F151-F178.
9. Reed JC. Balancing cell life and death: bax, apoptosis, and breast cancer. J Clin Invest 1996;97:2403-2404.
10. Vaux DL, Cory S, Adams JM. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 1988;335:440-442.
11. Marvel J, Perkins GR, Lopez Rivas A, et al. Growth factor starvation of bcl-2 overexpressing murine bone marrow cells induced refractoriness to IL-3 stimulation of proliferation. Oncogene 1994;9:1117-1122.
12. Pietenpol JA, Papadopoulos N, Markowitz S, et al. Paradoxical inhibition of solid tumor cell growth by bcl2. Cancer Res 1994;54:3714-3717.
13. Johnston SR, MacLennan KA, Sacks NP, et al. Modulation of Bcl-2 and Ki-67 expression in oestrogen receptor-positive human breast cancer by tamoxifen. Eur J Cancer 1994;30A:1663-1669.
14. Leek RD, Kaklamanis L, Pezzella F, et al. bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer. Br J Cancer 1994;69:135-139.
15. Joensuu H, Pylkkanen L, Toikkanen S. Bcl-2 protein expression and long-term survival in breast cancer. Am J Pathol 1994;145:1191-1198.
16. Silvestrini R, Veneroni S, Daidone MG, et al. The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst 1994;86:499-504.
17. Zhang GJ, Kimijima I, Abe R, et al. Apoptotic index correlates to bcl-2 and p53 protein expression, histo-logical grade and prognosis in invasive breast cancers. Anticancer Res 1998;18:1989-1998.
18. Krajewski S, Blomqvist C, Franssila K, et al. Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res 1995;55:4471-4478.
19. Elledge RM, Green S, Ciocca D, et al. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study. Clin Cancer Res 1998;4:7-12.
20. Kumar R, Vadlamudi RK, Adam L. Apoptosis in mammary gland and cancer. Endocr Relat Cancer 2000; 7:257-269.
21. Knowlton K, Mancini M, Creason S, et al. Bcl-2 slows in vitro breast cancer growth despite its antiapoptotic effect. J Surg Res 1998;76:22-26.
22. Teixeira C, Reed JC, Pratt MA. Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Res 1995;55:3902-3907.
23. Mimori K, Kataoka A, Yoshinaga K, et al. Identification of molecular markers for metastasis-related genes in primary breast cancer cells. Clin Exp Metastasis 2005;22:59-67.
24. Pinkas J, Martin SS, Leder P. Bcl-2-mediated cell survival promotes metastasis of EpH4 betaMEKDD mammary epithelial cells. Mol Cancer Res 2004;2: 551-556.
25. Kang MH, Reynolds CP. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res 2009;15:1126-1132.
26. Wu JM, Fackler MJ, Halushka MK, et al. Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases. Clin Cancer Res 2008;14:1938-1946.
27. Subhawong AP, Subhawong T, Nassar H, et al. Most basal-like breast carcinomas demonstrate the same Rb-/p16+ immunophenotype as the HPV-related poorly differentiated squamous cell carcinomas which they resemble morphologically. Am J Surg Pathol 2009;33:163-175.
28. Kristek J, Dm B, Kurbel S, et al. Tumor growth fraction, expression of estrogen and progesterone receptors, p53, bcl-2 and cathepsin D activity in primary ductal invasive breast carcinoma and their axillary lymph node metastases. Coll Antropol 2007; 31:1043-1047.
29. Arun B, Kilic G, Yen C, et al. Correlation of Bcl-2 and p53 expression in primary breast tumors and corresponding metastatic lymph nodes. Cancer 2003; 98:2554-2559.
30. D'Andrea MR, Limiti MR, Bari M, et al. Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis. Breast Cancer Res Treat 2007;101:279-284.